Key Takeaways
- A reset quarter, deliberately: Revenue grew just +3.6% CC in FY25 as management chose to correct trade inventory rather than push primary sales, sacrificing reported growth to build a healthier base for FY26.
- Strategy refresh targets double-digit CAGR by FY28: A McKinsey-informed seven-pillar plan anchors an ambition for sustainable double-digit top and bottom-line growth, with premiumization and portfolio exits as the headline shifts.
- Gross margins took a sharp hit: Standalone gross margin contracted ~247 bps in Q4 as 80% of the year's input inflation landed in the quarter, while competitive intensity limited price increases to ~3.5%.
- International delivered standout growth: The international business grew 19% CC, driven by MENA, Egypt, UK, USA, Turkey, and Bangladesh, providing a bright spot in an otherwise muted domestic quarter.
- What to watch next quarter: Whether the sequential improvement management promised actually materializes as Q1 laps a 7% base, and whether the premiumization push begins to show up in gross margin trajectory.
The Deliberate Inventory Reset
- Primary sacrificed for secondary health: Management deliberately reduced beverage loading by ~INR50-60 crores this season and held firm on not offering schemes to push stock, keeping trade inventory at a disciplined 21 days versus the prior 30 days.
- Wholesale bore the brunt: Because wholesale feeds rural markets, the inventory discipline caused wholesale primary to decline more than urban, even though rural tertiary offtake was resilient at 13%-14% growth per Nielsen.
- HPC base effects compounded the optics: Oral Care was lapping 22% growth and Odomos 20%-25% in the same quarter last year, so primary declined ~3% while secondary actually increased ~5%.
- The trade-off was explicit: Management judged that loading would have undone the entire inventory correction effort and returned the system to unhygienic levels, so they accepted the reported revenue hit.
Mohit Malhotra: "Had we loaded once again, then there was no point of doing any kind of inventory correction, we would have gone back to around the same level of unhygienic inventory. So we did not do that."
Strategy Refresh: Premiumization & Portfolio Rationalization
- A deliberate pivot after years of share consolidation: Management acknowledged that the past 4-5 years were spent gaining market share across categories, and premiumization was a lesser focus by design. The 2.0 journey now shifts toward contemporization and premium segments.
- Seven-pillar plan informed by McKinsey: The refreshed Vision strategy, anchored on seven key pillars, broadly reflects McKinsey's recommendations from an elaborate exercise covering live trends and analysis.
- Portfolio exits identified: Clear exit paths have been set for tea, baby diapers, sanitizing category, and Vita, which together represent less than 1% of revenue and are margin-dilutive with limited right to win.
- Premiumization guardrails are margin-accretive by design: Every new product launch must carry an accretive margin to the core product, lifting the overall gross margin profile rather than diluting it.
- Core brands get disproportionate investment: The eight INR500 crore+ brands (Dabur Red, Real, Chyawanprash, Honey, Hajmola, Amla, Odonil, Vatika) will receive continued investment to increase penetration and drive market share gains.
- Bold bets in healthcare: Management plans to ramp up the Hajmola franchise, health juices, and Shilajit, while also pursuing smaller pack sizes and new formats (gummies, powders, effervescents) to rebuild post-COVID penetration levels.
Mohit Malhotra: "If you look at past 4 to 5 years, we've generally focused on increasing market share and consolidating our business in each of the categories. But premiumisation has been lesser focus and it was a deliberate attempt... Now that we've done all the gain market shares... now it's 2.0 journey to embark upon premiumisation and contemporisation."
Category-Level Performance
| Category | Trend | Commentary |
|---|---|---|
| Skincare | ▲ Growth | Grew 8% driven by Gulabari. |
| Home Care | ▬ Low single-digit | Odonil performed well; Odomos impacted by unfavorable seasonality but gained 386 bps market share. |
| Oral Care | ▼ Sequentially down | Down 10%-12% QoQ on a 22% prior-year base; all brands gaining share, IDA certification received, court case won. |
| Hair Oils | ▬ Mixed | Shampoo grew ~4%; Hair Oils grew ahead of category with 196 bps share gain; Coconut Hair Oil grew 11%. |
| Health Supplements | ▼ Muted | Honey and Chyawanprash hit by delayed and contracted winters, though both gained share (162 bps and 75 bps). Glucose grew 10%. |
| Digestives | ▲ Modest growth | Hajmola franchise grew 3.3% with 233 bps share gain; Hajmola Zeera launch well received. |
| Health Juices | ▲ Strong | Grew 25% YoY. |
| Culinary | ▲ Strong | Grew 14% led by Hommade; Badshah grew 6% in Q4 (institutional sales hit by CSD budget cuts) but 12% for FY25. |
| Beverages | ▼ Impacted | Urban consumption slowdown (70% of portfolio is urban); premium segment did well with Real Activ and coconut water growing 11%; 261 bps share gain in J&N category. |
| International | ▲ Robust | 19% CC growth driven by MENA, Egypt, UK, USA, Turkey, and Bangladesh. |
Gross Margin Pressure & Pricing Dynamics
- Inflation concentrated in Q4: 80% of the full year's input inflation hit the fourth quarter, driving ~4.5%-5% inflation against price increases of only ~3.5%, constrained by competitive intensity.
- Trade promotions negated some pricing: The net realization benefit from price increases was partially offset by trade promotions, contributing to the ~247 bps standalone gross margin contraction.
- Category-wise pricing varied: Health Care took 4.5%-5% price increases, Personal Care 1.5%, and Beverages 1.6%, though management did not provide the blended Q4 weighted average pricing that was requested.
- New product margin guardrails as a structural fix: Going forward, every new product launch must have an accretive margin to the core product, which management expects will lift the overall gross margin profile over time.
Mohit Malhotra: "there will be specific guardrails where every new product launch will have to have an accretive margin to the core product of it. And therefore, it will lift the overall gross margin profile."
GTM Overhaul & Channel Strategy
- Urban general trade consolidation: Management plans to consolidate stockists in urban India to reduce cost to serve, increase span of control, and increase digitization, while emerging channels (e-commerce, quick commerce, modern trade) continue to grow in double digits.
- Rural expansion continues: The rural strategy focuses on expanding villages, expanding direct reach, and riding rural GTM infrastructure with INR10/INR20 bundle packs, supported by MSP increases and a 40% rise in MGNREGA outlay.
- Beverage GTM being fixed: The RPI versus colas has been corrected from 2.2-2.7x down to the INR99 price point, and Koolerz INR10/INR20 pet bottles plus coconut water are being made available in rural India.
- Hair care dual-track organization: Bottom-of-pyramid packs (INR10/20/50/100) ride rural infrastructure, while premium serums, masks, and conditioners target urban via e-commerce and modern trade with separate organizational structures.
M&A, Compliance & Adjacent Bets
- M&A pursuit is two-pronged: Management will aggressively pursue both revenue-accretive acquisitions and deals that create a future-fit portfolio for the new generation, focused on new-age healthcare, wellness foods, and premium personal care.
- M&A should bolster premiumization: The preference is to acquire a premium brand in the healthcare wellness space, which could extend to foods, while Personal Care M&A would be more organic.
- Plastic recycling compliance remains uncertain: Dabur is plastic-positive (recycling more than 100% of its plastic consumption) but use of recycled plastic in packaging is limited because capacity is low, recycled plastic is more expensive, and management is reluctant to use it in food and Ayurvedic products. Industry has represented to the government for more time, and rules are currently in abeyance.
- Therapeutics leadership transitioned: Mr. Philipe Haydon super-annuated and a new leader has joined; the focus on advocacy to promote Ayurveda to modern doctors continues, with a target to take the business from INR100 crore to INR200 crore.
Mohit Malhotra: "we are very reluctant to use recycled plastic in food products and also in our Ayurvedic product. Like in pharmaceutical industry, you don't use recycled plastic. So we are reluctant."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue growth | High single-digit, if not double-digit or near double-digit value growth; sequential improvement expected after Q1 laps a 7% base | FY26 full year |
| FY28 ambition | Sustainable double-digit CAGR in both top line and bottom line | By FY28 |
| Beverage growth | Low to mid-single digit for the beverage portfolio | FY26 |
| Premiumization journey | Begins from current quarter; every new product launch to have accretive margin to core product | Starting Q1 FY26 |
| Portfolio exits | Exit tea, baby diapers, sanitizing category, and Vita (less than 1% of revenue) | No date (underway) |
| Therapeutics scale-up | Grow from INR100 crore to INR200 crore turnover | No date given |
| GTM rekindlement | Urban stockist consolidation and rural expansion begin | Starting current year |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹12,563 cr (FY25), +3.6% YoY in constant currency |
| Consolidated revenue growth | +2.1% in constant currency, +0.6% in INR terms YoY |
| PAT | ₹1,768 cr (FY25) |
| India business revenue growth | -3.4% YoY |
| International business revenue growth | +19.3% in constant currency YoY |
| Standalone India gross margin contraction | ~247 bps YoY, driven by 4.5%–5% inflation vs 3.5% price increase |
| Overall price increase taken | ~3.5%, to flow through to Q1 FY26 |
| FY26 revenue growth guidance | High single-digit to near double-digit value growth for full year |
| Rural tertiary growth (Nielsen) | 13%–14% YoY, ahead of urban |
| Rural vs urban growth gap | Rural growing ~450 bps ahead of urban India |
| Inventory days correction | Reduced from 30 days to 21 days |
| Skincare growth | +8% YoY, driven by Gulabari |
| Oral Care prior-year base | +22% YoY in Q4 FY24 |
| Oral Care market share gain | 15–16 bps in Q4 |
| Hair Oils market share gain | 196 bps |
| Coconut Hair Oil growth | +11% YoY |
| Glucose growth | +10% YoY, market share gain of 112 bps |
| Hajmola franchise growth | +3.3% YoY, market share gain of 233 bps |
| Dabur Health Juices growth | +25% YoY |
| Culinary business growth | +14% YoY, led by Hommade |
| Badshah growth | +6% YoY in Q4, +12% in FY25 |
| Real Activ and coconut water growth | +11% YoY |
| J&N category market share gain | 261 bps |
| Odomos market share gain | 386 bps in MRC category |
| Odonil market share gain | 67 bps |
| Chyawanprash market share gain | 162 bps |
| Honey market share gain | 75 bps |
| Dabur Amla market share | 19.1%, all-time high, up from ~14% three years ago |
| Beverage loading reduction | ~₹50–60 cr less primary loading in season |
| Primary sales | -3% YoY (approx.) |
| Secondary sales | +5% YoY (approx.) |
| Categories identified for exit | Tea, baby diapers, Vita, breakfast cereals; contribute less than 1% of revenue |
| Food inflation | 2%–2.5% |
| Q1 FY25 base growth | ~7% YoY |
| Health Care CAGR | 7%–8% |
| Beverages CAGR | 10%+ |
| Odomos CAGR | 8%–10% |
| Oral Care CAGR | 9%–10% |
| Meswak growth | 10%–11% YoY |
| Herbal category share in modern trade | ~31%, up from 30% last year |
| Therapeutics business target | From ₹100 cr to ₹200 cr turnover |
| Medical practitioners addressed (therapeutics) | ~100,000 |
| Brands of ₹500 cr+ | 8 brands, contributing ~70% of portfolio |
| Hajmola extensions and variants contribution | >15% of Hajmola franchise |
| RPI vs Colas | Brought down to ₹99 price point, from 2.2–2.7 index |
| MGNREGA outlay increase | +40% in rural India |